VIRSTA Score for Infective Endocarditis Risk Assessment

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
virsta score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very Low Risk0–1
  • Higher Risk2–50
Direct Clinical Answer

The VIRSTA Score for Infective Endocarditis Risk Assessment calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include valve disease or prosthetic valve. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

The VIRSTA Score is a clinical decision tool used to risk-stratify suspected infective endocarditis cases before obtaining echocardiography. This score helps identify patients at very low risk for infective endocarditis who may not require immediate echocardiographic evaluation, thereby reducing unnecessary testing and healthcare costs while maintaining diagnostic safety.

Clinical Indication

The VIRSTA Score for Infective Endocarditis Risk Assessment is indicated for bedside clinical practice to support The VIRSTA Score is a clinical decision tool used to risk-stratify suspected infective endocarditis cases before obtaining echocardiography. This score helps identify patients at very low risk for infective endocarditis who may not require immediate echocardiographic evaluation, thereby reducing unnecessary testing and healthcare costs while maintaining diagnostic safety.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.

Limitations & Contraindications

In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.

Clinical Pearls & Action Plan

Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Validation studies have shown good discrimination ability (AUC 0.87-0.89).

Formula & Variables:

Sum of positive criteria: Valve disease/prosthetic valve (5 points) + Injection drug use (5 points) + Vascular phenomena (4 points) + Immunologic phenomena (3 points) + Systemic emboli (3 points) + Temperature >38°C (2 points) + Age >60 years (2 points) + WBC >11,000/μL (1 point) + Central venous catheter (1 point) + Staphylococcus aureus bacteremia (1 point)

Input Parameters

NameTypeRequiredDescription
valve_disease_or_prosthetic_valvestringYesPresence of known valve disease (including rheumatic heart disease, congenital valve disease, or degenerative valve disease) or prosthetic valve
injection_drug_usestringYesHistory of injection drug use (current or past)
vascular_phenomenastringYesPresence of vascular phenomena including major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, or Janeway lesions
immunologic_phenomenastringYesPresence of immunologic phenomena including glomerulonephritis, Osler nodes, Roth spots, or rheumatoid factor
systemic_embolistringYesEvidence of systemic arterial emboli (excluding those included in vascular phenomena)
temperature_over_38cstringYesFever with temperature greater than 38°C (100.4°F)
age_over_60stringYesPatient age greater than 60 years
wbc_over_11000stringYesWhite blood cell count greater than 11,000/μL (11.0 × 10⁹/L)
central_venous_catheterstringYesPresence of central venous catheter or other intravascular device
staph_aureus_bacteremiastringYesStaphylococcus aureus bacteremia (methicillin-sensitive or methicillin-resistant)

Score Interpretation & Guidance

RangeStageDescription
0–1Very Low RiskVery low probability of infective endocarditis
2–50Higher RiskIncreased probability of infective endocarditis

Evidence-Based References (EBM)

  • Sunnerhagen T, Törnell A, Vikbrant M, et al. VIRSTA score: prediction of infective endocarditis and mortality in Staphylococcus aureus bacteremia; a cohort study. Clin Microbiol Infect. 2019;25(4):480-486. doi: 10.1016/j.cmi.2018.06.021DOI: 10.1016/j.cmi.2018.06.021
  • Palraj BR, Baddour LM, Hess EP, et al. Predicting risk of endocarditis using a clinical tool (PREDICT): scoring system to guide use of echocardiography in the setting of Staphylococcus aureus bacteremia. Clin Infect Dis. 2015;61(1):18-28. doi: 10.1093/cid/civ235DOI: 10.1093/cid/civ235
  • Bouza E, Kestler M, Beca T, et al. The NOVA score: a proposal to reduce the need for transesophageal echocardiography in patients with enterococcal bacteremia. Clin Infect Dis. 2015;60(4):528-535. doi: 10.1093/cid/ciu872DOI: 10.1093/cid/ciu872

Related calculators